New Delhi, July 26, 2022 (GLOBE NEWSWIRE) — Global Peptide and Anticoagulant Drugs Market is flourishing owing to the rising number of cardiovascular diseases and technological advancements along with the emergence of new markets…
A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Peptide and Anticoagulant Drugs Market is projected to grow at a CAGR of 5.4%, earning revenues of around USD 2.15 billion by the end of 2028. The Global Peptide and Anticoagulant Drugs Market is booming because the prevalence of the chronic disease is rising internationally, in every region, and across all socioeconomic strata. Thus, the requirement for efficient therapies is accelerated by the rising prevalence of chronic diseases, which is anticipated to fuel the market for peptide and anticoagulant medications. Moreover, the market for peptides and anticoagulants is predicted to grow as a result of rising rates of ischemic heart disease, venous thromboembolism (VTE), and awareness of innovative oral anticoagulants (NOACs). Furthermore, Global Peptide and Anticoagulant Drugs Market is one of the most emerging markets that grow continuously owing to the rising public awareness of the benefits of early diagnostics. However, the high level of market consolidation and the availability of alternative drugs are impeding the global growth of the Peptide and Anticoagulant Drugs Market.
Increasing Number of…
